Navigation Links
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Date:4/9/2008

SOUTH SAN FRANCISCO, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present data on each of its clinical-stage anticancer compounds at the upcoming Annual Meeting of the American Association for Cancer Research (AACR) being held April 12-16 in San Diego, CA. Sunesis has built a portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell cycle and survival signaling.

Data from non-clinical studies of SNS-595, SNS-032 and SNS-314 will be presented in five posters and one oral presentation during the AACR Meeting. New insights on the mechanism of action and anticancer activity of SNS-595, Sunesis' lead compound, will be featured on Monday, April 14, 2008. SNS-595 is a novel naphthyridine analog structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 both selectively intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b combination clinical trial with cytarabine in relapsed/refractory acute myeloid leukemia are both ongoing.

SNS-595 Poster Presentations

Monday, April 14, 2008

-- SNS-595 is a potent anti-tumor agent that has a dual mechanism of

action: DNA intercalation and site-selective topoisomerase II poisoning

Session: Stress Responses

Abstract #1860

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

-- Sensitivity to SNS-595 is related to activation of double strand DNA

break repair pathways including homologous recombination

Session: Stress Responses

Abstract #1859

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

-- Ex vivo activity of SNS-595 against biopsies of acute myeloid leukemia,

triple negative breast and ovarian cancers supports ongoing and

potential clinical indications

Session: Novel Drug Targets, Agents and Mechanisms

Abstract #2830

1:00 p.m. - 5:00 p.m. Exhibit Hall B-F, San Diego Convention Center

Suzanne Trudel, MSc, M.D., Assistant Professor, Princess Margaret Hospital, University Health Network, will provide an oral presentation on SNS-032's preclinical activity in multiple myeloma as part of a minisymposium on Tuesday, April 15, 2008. In addition, translational research data detailing the relationship between SNS-032's mechanism and its activity in certain types of cancer will be presented in a poster. SNS-032, a potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory chronic lymphocytic leukemia or multiple myeloma.

SNS-032 Oral Presentation

Tuesday, April 15, 2008

-- SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates

preclinical activity in human multiple myeloma

Minisymposium: Novel Genomic Approaches, Drugs, Targets, and Strategies

Abstract #4972

4:55 p.m. to 5:10 p.m. Room 30A-C, San Diego Convention Center

SNS-032 Poster Presentation

Sunday, April 13, 2008

-- SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7, and 9,

blocks transcription of cyclin D1 and Mcl-1, causing cell death in

mantle cell lymphoma cell lines

Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors

Abstract #756

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

Preclinical data providing new details on SNS-314's anti-tumor activity will be presented Wednesday, April 16, 2008. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.

SNS-314 Poster Presentation

Wednesday, April 16, 2008

-- SNS-314, a potent inhibitor of Aurora kinases, has preclinical

anti-activity and induces apoptosis

Session: Heat Shock Protein Inhibitors, Aurora Kinase and other Mitotic

Inhibitors

Abstract #5648

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
2. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
9. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
Breaking Medicine News(10 mins):